PASADENA, Calif., November 18, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you